Abstract
The clinical management of neuropathic pain is particularly challenging. Current therapies for neuropathic pain modulate nerve impulse propagation or synaptic transmission; these therapies are of limited benefit and have undesirable side effects. Injuries to peripheral nerves result in a host of pathophysiological changes associated with the sustained expression of abnormal pain. Here we show that systemic, intermittent administration of artemin produces dose- and time-related reversal of nerve injury–induced pain behavior, together with partial to complete normalization of multiple morphological and neurochemical features of the injury state. These effects of artemin were sustained for at least 28 days. Higher doses of artemin than those completely reversing experimental neuropathic pain did not elicit sensory or motor abnormalities. Our results indicate that the behavioral symptoms of neuropathic pain states can be treated successfully, and that partial to complete reversal of associated morphological and neurochemical changes is achievable with artemin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lin, L.F., Doherty, D.H., Lile, J.D., Bektesh, S. & Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130–1132 (1993).
Kotzbauer, P.T. et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384, 467–470 (1996).
Milbrandt, J. et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20, 245–253 (1998).
Masure, S. et al. Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. Existence and tissue-specific expression of different splice variants. Eur. J. Biochem. 266, 892–902 (1999).
Rosenblad, C. et al. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol. Cell. Neurosci. 15, 199–214 (2000).
Worby, C.A. et al. Identification and characterization of GFR-alpha3, a novel co-receptor belonging to the glial cell line-derived neurotrophic receptor family. J. Biol. Chem. 273, 3502–3508 (1998).
Treanor, J.J. et al. Characterization of a multicomponent receptor for GDNF. Nature 382, 80–83 (1996).
Sanicola, M. et al. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. Proc. Natl. Acad. Sci. USA 94, 6238–6243 (1997).
Naveilhan, P. et al. Expression and regulation of GFR-alpha3, a glial cell line-derived neurotrophic factor family receptor. Proc. Natl. Acad. Sci. USA 95, 1295–1300 (1998).
Jing, S. et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85, 1113–1124 (1996).
Baloh, R.H. et al. GFR-alpha3 is an orphan member of the GDNF/neurturin/persephin receptor family. Proc. Natl. Acad. Sci. USA 95, 5801–5806 (1998).
Baloh, R.H. et al. TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron 18, 793–802 (1997).
Baloh, R.H. et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFR-alpha3-RET receptor complex. Neuron 21, 1291–1302 (1998).
Enokido, Y. et al. GFR- alpha-4 and the tyrosine kinase Ret form a functional receptor complex for persephin. Curr. Biol. 8, 1019–1022 (1998).
Klein, R.D. et al. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 387, 717–721 (1997).
Widenfalk, J., Tomac, A., Lindqvist, E., Hoffer, B. & Olson, L. GFR-alpha3, a protein related to GFR-alpha1, is expressed in developing peripheral neurons and ensheathing cells. Eur. J. Neurosci. 10, 1508–1517 (1998).
Orozco, O.E., Walus, L., Sah, D.W., Pepinsky, R.B. & Sanicola, M. GFR-alpha3 is expressed predominantly in nociceptive sensory neurons. Eur. J. Neurosci. 13, 2177–2182 (2001).
Payne, R. Neuropathic pain syndromes, with special reference to causalgia and reflex sympathetic dystrophy. Clin. J. Pain 2, 59–73 (1986).
Merskey, H. & Bogduk, N. 2nd edn. (eds. Merskey, H. & Bogduk, N.) Classifications of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms 40–43 (IASP Press, Seattle, 1994).
Malan, T.P. et al. Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. Pain 86, 185–194 (2000).
Gardell, L.R. et al. Increased evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J. Neurosci. 23, 8370–8379 (2003).
Lai, J. et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 95, 143–152 (2002).
Bennett, D.L. et al. A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury. J. Neurosci. 18, 3059–3072 (1998).
Bennett, D.L. et al. The glial cell line-derived neurotrophic factor family receptor components are differentially regulated within sensory neurons after nerve injury. J. Neurosci. 20, 427–437 (2000).
Molliver, D.C., Radeke, M.J., Feinstein, S.C. & Snider, W.D. Presence or absence of TrkA protein distinguishes subsets of small sensory neurons with unique cytochemical characteristics and dorsal horn projections. J. Comp. Neurol. 361, 404–416 (1995).
Ossipov, M.H. et al. Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y. J. Neurosci. 22, 9858–9867 (2002).
Acheson, A. & Lindsay, R.M. Non target-derived roles of the neurotrophins. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351, 417–422 (1996).
Nichols, M.L. et al. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 286, 1558–1561 (1999).
Porreca, F. et al. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc. Natl. Acad. Sci. USA 96, 7640–7644 (1999).
Burgess, S.E. et al. Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J. Neurosci. 22, 5129–5136 (2002).
Wang, Z. et al. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci. 21, 1779–1786 (2001).
Suzuki, R., Morcuende, S., Webber, M., Hunt, S.P. & Dickenson, A.H. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat. Neurosci. 5, 1319–1326 (2002).
Porreca, F., Ossipov, M.H. & Gebhart, G.F. Chronic pain and medullary descending facilitation. Trends Neurosci. 25, 319–325 (2002).
Ossipov, M.H., Lai, J., Malan, T.P., Jr., Vanderah, T.W. & Porreca, F. Tonic descending facilitation as a mechanism of neuropathic pain. in Neuropatic Pain: Pathophysiology and Treatment (eds. Hansson, P.T., Fields, H.L., Hill, R.G. & Marchettini, P.) 107–124 (IASP Press, Seattle, 2001).
Devor, M. & Seltzer, Z. Pathophysiology of damaged nerves in relation to chronic pain. in Textbook of Pain (eds. Wall, P.D. & Melzack, R.) 129–164 (Churchill Livingstone, London, 1999).
Liu, X., Eschenfelder, S., Blenk, K.H., Janig, W. & Habler, H. Spontaneous activity of axotomized afferent neurons after L5 spinal nerve injury in rats. Pain 84, 309–318 (2000).
Vollmer, K.O., von Hodenberg, A. & Kolle, E.U. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 36, 830–839 (1986).
Boucher, T.J. et al. Potent analgesic effects of GDNF in neuropathic pain states. Science 290, 124–127 (2000).
Wu, G. et al. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J. Neurosci. 21, RC140 (2001).
McQuay, H.J. et al. Opioid sensitivity of chronic pain: a patient-controlled analgesia method. Anaesthesia 47, 757–767 (1992).
Portenoy, R.K., Foley, K.M. & Inturrisi, C.E. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 43, 273–286 (1990).
Rowbotham, M.C., Reisner-Keller, L.A. & Fields, H.L. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41, 1024–1028 (1991).
Rose, M.A. & Kam, P.C. Gabapentin: pharmacology and its use in pain management. Anaesthesia 57, 451–462 (2002).
Trupp, M., Raynoschek, C., Belluardo, N. & Ibanez, C.F. Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase. Mol. Cell. Neurosci. 11, 47–63 (1998).
Kim, S.H. & Chung, J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50, 355–363 (1992).
Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M. & Yaksh, T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–63 (1994).
Chen, J.J., Barber, L.A., Dymshitz, J. & Vasko, M.R. Peptidase inhibitors improve recovery of substance P and calcitonin gene-related peptide release from rat spinal cord slices. Peptides 17, 31–37 (1996).
Gardell, L.R. et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J. Neurosci. 22, 6747–6755 (2002).
Ehrenfels, C.W., Carmillo, P.J., Orozco, O., Cate, R.L. & Sanicola, M. Perturbation of RET signaling in the embryonic kidney. Dev. Genet. 24, 263–272 (1999).
Guo, A., Vulchanova, L., Wang, J., Li, X. & Elde, R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB-4 binding sites. Eur. J. Neurosci. 11, 946–958 (1999).
Acknowledgements
The authors thank S. Burgess, L. Majuta, K. Vault and C. Zhong for technical assistance; M. McAuliffe, B. Coleman and C. Tonkin for DNA sequencing; R. Boynton, A. Kaffashan, D. Mo, D. Wen and C. Young for protein sequencing and characterization; and the Biogen Media Preparation Group.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
These studies were supported by a grant from Biogen Inc.
Rights and permissions
About this article
Cite this article
Gardell, L., Wang, R., Ehrenfels, C. et al. Multiple actions of systemic artemin in experimental neuropathy. Nat Med 9, 1383–1389 (2003). https://doi.org/10.1038/nm944
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm944
This article is cited by
-
Transcriptional profiles of TGF-β superfamily members in the lumbar DRGs and the effects of activins A and C on inflammatory pain in rats
Journal of Physiology and Biochemistry (2023)
-
Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson’s disease
Cell and Tissue Research (2020)
-
Investigating the Role of Artemin Glycosylation
Pharmaceutical Research (2016)
-
Peripherally Increased Artemin is a Key Regulator of TRPA1/V1 Expression in Primary Afferent Neurons
Molecular Pain (2015)
-
Artemin Growth Factor Increases Nicotinic Cholinergic Receptor Subunit Expression and Activity in Nociceptive Sensory Neurons
Molecular Pain (2014)